07:01 Tue 26 Jan 2021
Omega Diagnostics Gp - Update re AbC-19 Rapid Test
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Update re AbC-19TM Rapid Test &
Launch of COVID-19 antibody laboratory-based testing service
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes today's update from Abingdon Health plc (AIM: ABDX) ("Abingdon Health") regarding the AbC-19TM Rapid Test, confirming their expectations for future supply arrangements with the Department of Health and Social Care, the ongoing efforts to obtain regulatory approvals in a total of 27 geographies, and the ongoing work to build data the set(s) around the use-case for the AbC-19TM Rapid Test alongside vaccines.
In addition, Omega will today announce the launch of its COVID-19 antibody lab-based testing service in Littleport,
1ELISA (Enzyme Linked Immuno-Sorbent Assay)
Contacts:
Omega Diagnostics Group PLC |
Tel: 01259 763 030 |
|
|
|
|
|
|
finnCap Ltd |
Tel: 020 7220 0500 |
Geoff Nash/Edward Whiley (Corporate Finance) |
|
|
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul McManus |
Mob: 07980 541 893 |
Lianne Cawthorne |
Mob: 07584 391 303 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE